HRP20110637T1 - Metoda liječenja pacijenata sa hepatitisom c - Google Patents
Metoda liječenja pacijenata sa hepatitisom c Download PDFInfo
- Publication number
- HRP20110637T1 HRP20110637T1 HR20110637T HRP20110637T HRP20110637T1 HR P20110637 T1 HRP20110637 T1 HR P20110637T1 HR 20110637 T HR20110637 T HR 20110637T HR P20110637 T HRP20110637 T HR P20110637T HR P20110637 T1 HRP20110637 T1 HR P20110637T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- period
- use according
- patient
- image
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 6
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 208000005176 Hepatitis C Diseases 0.000 claims abstract 3
- 208000010710 hepatitis C virus infection Diseases 0.000 claims abstract 3
- 150000001875 compounds Chemical group 0.000 claims 14
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 10
- 229960000329 ribavirin Drugs 0.000 claims 10
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 10
- 108010050904 Interferons Proteins 0.000 claims 9
- 102000014150 Interferons Human genes 0.000 claims 9
- 229940079322 interferon Drugs 0.000 claims 9
- 229940122604 HCV protease inhibitor Drugs 0.000 claims 7
- 230000037396 body weight Effects 0.000 claims 7
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 229950000038 interferon alfa Drugs 0.000 claims 4
- 229960000517 boceprevir Drugs 0.000 claims 3
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims 2
- 229960003931 peginterferon alfa-2b Drugs 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Kompozicija koja sadrži najmanje jedan spoj - inhibitor HCV proteaze, naznačena time, što je izabran između spojeva koja imaju formulu: ii izomera spomenutih spojeva, za primjenu u metodi liječenja pacijenta koji ima hepatitis C infekciju, a koji nije prethodno liječen ili koji je recidivirao iz negativnog HCV statusa i onda je bio liječen ribavirinom i interferonom tokom uvodnog perioda, pri čemu ova metoda sadrži korak (i) na kraju spomenutog uvodnog perioda davanje kombinacije ribavirina, interferona i spoja - inhibitora HCV proteaze tokom drugog perioda liječenja koji ima dovoljno dugo trajanje da se ostvari prisustvo virusa koje se ne može detektirati primjenom HCV-RNK testa. Patent sadrži još 19 patentnih zahtjeva.
Claims (20)
1. Kompozicija koja sadrži najmanje jedan spoj - inhibitor HCV proteaze, naznačena time, što je izabran između spojeva koja imaju formulu:
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
i izomera spomenutih spojeva,
za primjenu u metodi liječenja pacijenta koji ima hepatitis C infekciju, a koji nije prethodno liječen ili koji je recidivirao iz negativnog HCV statusa i onda je bio liječen ribavirinom i interferonom tokom uvodnog perioda, pri čemu ova metoda sadrži korak (i) na kraju spomenutog uvodnog perioda davanje kombinacije ribavirina, interferona i spoja - inhibitora HCV proteaze tokom drugog perioda liječenja koji ima dovoljno dugo trajanje da se ostvari prisustvo virusa koje se ne može detektirati primjenom HCV-RNK testa.
2. Kompozicija koja sadrži interferon, naznačena time što se koristi za primjenu u metodi liječenja pacijenta koji ima hepatitis C infekciju, a koji nije prethodno liječen ili koji je recidivirao iz negativnog HCV statusa i onda je bio liječen ribavirinom i interferonom tokom uvodnog perioda, pri čemu ova metoda sadrži korake
(a) davanje kombinacije ribavirina i interferona tokom uvodnog perioda;
(b) na kraju spomenutog uvodnog perioda davanje kombinacije ribavirina, interferona i najmanje jednog spoja - inhibitora HCV proteaze tokom drugog perioda liječenja koji traje dovoljno dugo da se ostvari prisustvo virusa koje se ne može detektirati primjenom HCV-RNK testa,
pri čemu je spoj - inhibitor HCV proteaze izabran između spojeva koji imaju formulu:
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
i izomera spomenutih spojeva.
3. Kompozicija za primjenu prema bilo kojem od zahtjeva 1-2, naznačena time što je interferon koji se daje tokom uvodnog perioda i/ili drugog perioda liječenja pegilirani interferon alfa ili fuzija između humanog serumskog albumina i interferona alfa.
4. Kompozicija za primjenu prema zahtjevu 3, naznačena time, što je interferon koji se daje tokom uvodnog perioda i/ili drugog perioda liječenja peginterferon alfa-2b i količina koja se daje je od 0,5 mikrograma/kg tjelesne težine pacijenta do 1,5 mikrograma/kg tjelesne težine pacijenta po rasporedu davanja jednom tjedno.
5. Kompozicija za primjenu prema bilo kojem od prethodnih zahtjeva, naznačena time što je spoj - inhibitor HCV proteaze spoj Formule Ia (boceprevir).
6. Kompozicija za primjenu prema zahtjevu 5, naznačena time što je količina boceprevira koja se daje 800 mg u intervalima od 7 sati do 9 sati.
7. Kompozicija za primjenu prema bilo kojem od prethodnih zahtjeva, naznačena time, što je spoj - inhibitor HCV proteaze spoj Formule III.
8. Kompozicija za primjenu prema bilo kojem od zahtjeva 1 do 7, naznačena time što je količina ribavirina koja se daje od 10 mg/kg tjelesne težine pacijenta do 20 mg/kg tjelesne težine pacijenta dnevno.
9. Kompozicija za primjenu prema zahtjevu 8, naznačena time što je količina ribavirina koja se daje i tokom uvodnog perioda, i tokom drugog perioda liječenja 16 mg/kg tjelesne težine pacijenta podijeljena na dva dijela koja se daju u razmaku od 12 sati.
10. Kompozicija za primjenu prema bilo kojem od zahtjeva 1 do 9, naznačena time što čemu uvodni period traje od 2 tjedna do 17 tjedena.
11. Kompozicija za primjenu prema zahtjevu 10, naznačena time što uvodni period traje četiri tjedna.
12. Kompozicija za primjenu prema zahtjevu 11, naznačena time što drugi period liječenja traje od 12 tjedna do 28 tjedana.
13. Kompozicija za primjenu prema zahtjevu 10, naznačena time što drugi period liječenja traje dovoljno dugo da se ostvari trajni virološki odgovor.
14. Kompozicija za primjenu prema bilo kojem od zahtjeva 1 do 13, naznačena time što pacijent nije prethodno liječen.
15. Kompozicija za primjenu prema bilo kojem od zahtjeva 1 do 13, naznačena time što pacijent nije reagirao na prethodno liječenje interferonom alfa i ribavirinom.
16. Kompozicija za primjenu prema bilo kojem od zahtjeva 1 do 13, naznačena time što je pacijent recidivirao poslije prethodnog tretmana interferonom alfa i ribavirinom.
17. Kompozicija za primjenu prema bilo kojem od zahtjeva 1 do 16, naznačen time što je pacijent inficiran genotipom 1 HCV.
18. Kompozicija za primjenu prema bilo kojem od zahtjeva 1-2, naznačena time što je spoj - inhibitor HCV proteaze spoj Formule Ia (boceprevir) i količina koja se daje je 800 mg u intervalima od 7 sati do 9 sati, a interferon je peginterferon alfa-2b i količina koja se daje je 1,5 mikrograma/kg tjelesne težine pacijenta po rasporedu davanja jednom tjedno i količina ribavirina koja se daje je 16 mg/kg tjelesne težine pacijenta dnevno podijeljena u dva dijela koja se daju u razmaku od 12 sati.
19. Kompozicija za primjenu prema bilo kojem od zahtjeva 1 do 18, naznačena time što je na kraju uvodnog perioda kod pacijenta došlo do pada virusnog opterećenja od 2 log ili većeg.
20. Kompozicija za primjenu prema zahtjevu 18, naznačena time što je prije uvodnog perioda pacijent imao virusno opterećenje >600.000 IU/mL HCV.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99375307P | 2007-09-14 | 2007-09-14 | |
| US99876207P | 2007-10-12 | 2007-10-12 | |
| US149407P | 2007-10-30 | 2007-10-30 | |
| PCT/US2008/010626 WO2009038663A1 (en) | 2007-09-14 | 2008-09-11 | Method of treating hepatitis c patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110637T1 true HRP20110637T1 (hr) | 2011-10-31 |
Family
ID=40262964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110637T HRP20110637T1 (hr) | 2007-09-14 | 2011-09-07 | Metoda liječenja pacijenata sa hepatitisom c |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100226885A1 (hr) |
| EP (2) | EP2061513B1 (hr) |
| JP (1) | JP2010539165A (hr) |
| CN (1) | CN101883590A (hr) |
| AT (1) | ATE519503T1 (hr) |
| AU (1) | AU2008301981A1 (hr) |
| CA (1) | CA2699280A1 (hr) |
| CY (1) | CY1112116T1 (hr) |
| DK (1) | DK2061513T3 (hr) |
| ES (1) | ES2369321T3 (hr) |
| HK (1) | HK1129315A1 (hr) |
| HR (1) | HRP20110637T1 (hr) |
| MX (1) | MX2010002909A (hr) |
| NZ (1) | NZ583825A (hr) |
| PL (1) | PL2061513T3 (hr) |
| PT (1) | PT2061513E (hr) |
| SI (1) | SI2061513T1 (hr) |
| WO (1) | WO2009038663A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| EP2704570A4 (en) * | 2011-05-04 | 2015-02-18 | Merck Sharp & Dohme | ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
| SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2012332827A1 (en) | 2011-10-31 | 2014-05-15 | Gilead Pharmasset Llc | Methods and compositions for treating hepatitis C virus |
| AU2012346217B2 (en) * | 2011-11-29 | 2016-02-04 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| WO2013116592A1 (en) | 2012-02-01 | 2013-08-08 | Kadmon Pharmaceuticals, Llc | Once daily treatment of hepatitis c with ribavirin and taribavirin |
| SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000037110A2 (en) * | 1998-12-18 | 2000-06-29 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
| US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
| WO2000051631A2 (en) * | 1999-03-02 | 2000-09-08 | Schering Corporation | Pegylated alpha interferon for hiv therapy |
| PL206255B1 (pl) * | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| PT1730110E (pt) | 2004-02-27 | 2010-09-14 | Schering Corp | Compostos de enxofre como inibidores de serina-protease ns3 do vírus da hepatite c |
| WO2006016930A2 (en) * | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
| WO2006130553A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
| US20070274951A1 (en) | 2006-02-09 | 2007-11-29 | Xiao Tong | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto |
| AU2009256623A1 (en) * | 2008-06-10 | 2009-12-17 | Janssen Pharmaceutica Nv | Telaprevir dosing regimen |
-
2008
- 2008-09-11 CA CA2699280A patent/CA2699280A1/en not_active Abandoned
- 2008-09-11 AU AU2008301981A patent/AU2008301981A1/en not_active Abandoned
- 2008-09-11 MX MX2010002909A patent/MX2010002909A/es not_active Application Discontinuation
- 2008-09-11 WO PCT/US2008/010626 patent/WO2009038663A1/en active Application Filing
- 2008-09-11 PT PT08831728T patent/PT2061513E/pt unknown
- 2008-09-11 AT AT08831728T patent/ATE519503T1/de active
- 2008-09-11 US US12/376,180 patent/US20100226885A1/en not_active Abandoned
- 2008-09-11 NZ NZ583825A patent/NZ583825A/en not_active IP Right Cessation
- 2008-09-11 CN CN200880116595XA patent/CN101883590A/zh active Pending
- 2008-09-11 DK DK08831728.4T patent/DK2061513T3/da active
- 2008-09-11 JP JP2010524864A patent/JP2010539165A/ja active Pending
- 2008-09-11 SI SI200830406T patent/SI2061513T1/sl unknown
- 2008-09-11 EP EP08831728A patent/EP2061513B1/en not_active Revoked
- 2008-09-11 EP EP11176964A patent/EP2489369A1/en not_active Withdrawn
- 2008-09-11 ES ES08831728T patent/ES2369321T3/es active Active
- 2008-09-11 PL PL08831728T patent/PL2061513T3/pl unknown
-
2009
- 2009-09-14 HK HK09108390.0A patent/HK1129315A1/xx not_active IP Right Cessation
-
2011
- 2011-09-07 HR HR20110637T patent/HRP20110637T1/hr unknown
- 2011-11-01 CY CY20111101045T patent/CY1112116T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE519503T1 (de) | 2011-08-15 |
| EP2489369A1 (en) | 2012-08-22 |
| AU2008301981A1 (en) | 2009-03-26 |
| PT2061513E (pt) | 2011-10-17 |
| US20100226885A1 (en) | 2010-09-09 |
| CA2699280A1 (en) | 2009-03-26 |
| EP2061513B1 (en) | 2011-08-10 |
| PL2061513T3 (pl) | 2011-12-30 |
| CY1112116T1 (el) | 2015-11-04 |
| MX2010002909A (es) | 2010-03-30 |
| SI2061513T1 (sl) | 2011-11-30 |
| DK2061513T3 (da) | 2011-11-21 |
| HK1129315A1 (en) | 2009-11-27 |
| ES2369321T3 (es) | 2011-11-29 |
| JP2010539165A (ja) | 2010-12-16 |
| WO2009038663A1 (en) | 2009-03-26 |
| CN101883590A (zh) | 2010-11-10 |
| EP2061513A1 (en) | 2009-05-27 |
| NZ583825A (en) | 2012-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110637T1 (hr) | Metoda liječenja pacijenata sa hepatitisom c | |
| ES2659216T3 (es) | Métodos para el tratamiento del VHC | |
| Manns et al. | Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1 | |
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| NZ502740A (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| JP2007522237A5 (hr) | ||
| JP2008518943A5 (hr) | ||
| RU2010153688A (ru) | Режим дозирования телапревира | |
| Namba et al. | Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy | |
| Ciancio et al. | Thymosin alpha‐1 with peginterferon alfa‐2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? | |
| US20140249101A1 (en) | Methods for treating hepatitis c virus infection | |
| EP2050459B1 (en) | Prophylactic or therapeutic agent for viral disease | |
| Moskovitz et al. | High Dose Consensus Interferon in Nonresponders to Interferon Alpha‐2B and Ribavirin with Chronic Hepatitis C | |
| Forns et al. | 56 ON-TREATMENT RESPONSE-GUIDED THERAPY WITH TELAPREVIR Q8H OR Q12H COMBINED WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C (STUDY C208) | |
| Jensen et al. | Future directions in therapy for chronic hepatitis C | |
| Nasser et al. | Recent trends in chronic hepatitis C virus treatment | |
| WO2006131566A3 (en) | Oral ribavirin pharmaceutical compositions | |
| Garg et al. | Management of HCV infection: current issues and future options | |
| Krastev et al. | Inosine pranobex (Isoprinosine)–a potential adjuvant in the management of chronic HBV infection | |
| US20150328280A1 (en) | Alisporivr for treatment of hepatitis c virus infection | |
| Sologub et al. | Efficacy and safety of the drug Ukrain in chronic hepatitis C patients | |
| Raza et al. | Hepatic Profile in the Patients receiving hepatitis treatment | |
| Stavar et al. | Considerations on Direct Antiviral Agent Therapy in Patients Having Chronic Hepatitis C from Constanta County | |
| DK1311279T3 (da) | Behandling af hepatitis C med thymosin, interferon og ribavirin | |
| Sorbera | Albinterferon alfa-2b |